Literature DB >> 8415832

Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys.

A V Terry1, J J Buccafusco, W J Jackson.   

Abstract

The basis for the memory enhancing action of nicotine was evaluated in five adult monkeys (Macaca fascicularis) well trained in the performance of a delayed matching-to-sample (DMTS) paradigm. Nicotine (1.25-20 micrograms/kg, IM) produced a dose-dependent improvement in performance of the task. The optimal dose of nicotine for each monkey also improved performance when the animals were tested 24 h later in the no-drug situation. In the same animals, low doses of scopolamine produced a dose-dependent decrement in DMTS performance. A subthreshold dose (defined by DMTS performance decrement) of scopolamine was administered 20 min prior to the optimal dose of nicotine. Scopolamine pretreatment completely blocked the enhanced performance observed earlier with nicotine. The results of this study are consistent with the hypothesis that the enhanced cognitive performance associated with nicotine is due to central acetylcholine release and subsequent muscarinic receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415832     DOI: 10.1016/0091-3057(93)90141-f

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

Review 1.  A preclinical cognitive test battery to parallel the National Institute of Health Toolbox in humans: bridging the translational gap.

Authors:  Shikha Snigdha; Norton W Milgram; Sherry L Willis; Marylin Albert; S Weintraub; Norbert J Fortin; Carl W Cotman
Journal:  Neurobiol Aging       Date:  2013-02-20       Impact factor: 4.673

Review 2.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

3.  The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats.

Authors:  Alvin V Terry; Jerry J Buccafusco; R Foster Schade; Leah Vandenhuerk; Patrick M Callahan; Wayne D Beck; Elizabeth J Hutchings; James M Chapman; Pei Li; Michael G Bartlett
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

4.  Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement.

Authors:  J J Buccafusco; W J Jackson; A V Terry; K C Marsh; M W Decker; S P Arneric
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

Review 5.  Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  J Psychiatry Neurosci       Date:  2006-11       Impact factor: 6.186

6.  Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.

Authors:  J Turchi; L A Holley; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  A critical examination of best dose analysis for determining cognitive-enhancing potential of drugs: studies with rhesus monkeys and computer simulations.

Authors:  Paul L Soto; Jesse Dallery; Nancy A Ator; Brian R Katz
Journal:  Psychopharmacology (Berl)       Date:  2013-03-26       Impact factor: 4.530

8.  Effects of nicotine and mecamylamine on cognition in rhesus monkeys.

Authors:  Simon N Katner; Sophia A Davis; Amber J Kirsten; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

9.  Nicotine improves delayed recognition in schizophrenic patients.

Authors:  Carol S Myers; Olalla Robles; A Nancy Kakoyannis; Jay D Sherr; Matthew T Avila; Teresa A Blaxton; Gunvant K Thaker
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

Review 10.  Cognition as a therapeutic target in late-life depression: potential for nicotinic therapeutics.

Authors:  Lilia Zurkovsky; Warren D Taylor; Paul A Newhouse
Journal:  Biochem Pharmacol       Date:  2013-08-08       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.